Geneva Capital Management LLC reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 12.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 507,779 shares of the medical equipment provider’s stock after selling 74,362 shares during the period. Geneva Capital Management LLC’s holdings in BioLife Solutions were worth $19,727,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in BioLife Solutions in the 2nd quarter valued at $3,754,000. Tidal Investments LLC acquired a new stake in shares of BioLife Solutions in the 2nd quarter worth $819,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of BioLife Solutions in the 2nd quarter worth $4,346,000. Hsbc Holdings PLC acquired a new stake in shares of BioLife Solutions in the 1st quarter worth $874,000. Finally, Ranger Investment Management L.P. purchased a new stake in shares of BioLife Solutions in the second quarter valued at about $6,736,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Lake Street Capital lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the stock from $33.00 to $31.00 in a research note on Wednesday, July 22nd. Stephens cut shares of BioLife Solutions from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $32.00 to $31.00 in a report on Monday, July 27th. Maxim Group downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Benchmark lowered BioLife Solutions from a “buy” rating to a “hold” rating in a report on Monday, August 10th. Finally, Craig Hallum lowered BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $31.38.
BioLife Solutions Price Performance
NASDAQ:BLFS opened at $38.61 on Monday. The firm’s fifty day simple moving average is $37.93 and its 200-day simple moving average is $28.64. The stock has a market cap of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82. BioLife Solutions, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $39.76.
BioLife Solutions Profile
BioLife Solutions, Inc. develops and supplies products and services used in the development and commercial production of cell and gene therapies and other biologic medicines. Its offerings support the handling, preservation, storage and distribution of sensitive biological materials. The company’s products include CryoStor and HypoThermosol preservation media, as well as CellSeal bags designed for cryogenic storage. BioLife also provides temperature-controlled storage and repository services for biological materials through its SciSafe business.
Further Reading
- Five stocks we like better than BioLife Solutions
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report).
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
